Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET-FIRST
2024-519854-35-00Phase 4Completed
- Sponsor
- MicroPort EverPace
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised trial in myocardial infarction (MI), Non-ST-segment elevation myocardial infarction (NSTEMI) and acute ST-segment elevation myocardial infarction (STEMI) comparing Aspirin + prasugrel, Aspirin + ticagrelor and Aspirin + clopidogrel (3 arms). Primary endpoint: Net Adverse Clinical and Cerebral Events (NACCE). Started Jan 2025; status: completed.
02
Drugs
prasugrelticagrelorclopidogrelaspirin
03
Conditions
myocardial infarction (MI)Non-ST-segment elevation myocardial infarction (NSTEMI)acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on 2024-519854-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519854-35-00.